UNSPSC 51183504: Linogliride

This classification denotes an anti-diabetic agent with the molecular formula C16H22N4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 7E521JYJ4X, chemically known as 4-morpholinecarboximidamide, n-(1-methyl-2-pyrrolidinylidene)-n-phenyl- but more generally known as linogliride, which bears US NIH Compound Identifier 6536869. European Medicines Agency schedules Linogliride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08521MIG.

UNSPSC 51183504 Linogliride, a Commodity code, encompasses diabetes and metabolic-disorder pharmaceutical products procured by state and local health systems and cooperative purchasing alliances. State and local governments acquire linogliride and related generic pharmaceuticals through multi-state cooperative agreements that consolidate purchasing across participating jurisdictions and authorized pharmaceutical wholesalers, reducing unit costs and streamlining supply-chain logistics. The sourcing model emphasizes compliance with cGMP and DSCSA requirements, NDC-specific product specifications, and contractual relationships with authorized distribution channels. Cooperative purchasing alliances such as MMCAP (Minnesota Multistate Cooperative Purchasing Alliance) serve as primary issuing bodies, extending procurement reach across multiple states and diverse public entities including state health departments, local government facilities, and participating member jurisdictions.

MMCAP's January 2026 RFP for Generic Multi Source Pharmaceuticals and OTC Products (Solicitation Number S1070000015802, due March 26, 2026) represents current activity under this code. The RFP establishes multiple contracts for pharmaceutical manufacturers to supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with awarded vendors effective July 1, 2026. Evaluation weighting prioritizes price competitiveness (75 percent), fixed pricing and compliance (10 and 5 percent respectively), EDI capability (5 percent), and administrative-fee acceptance (5 percent). Vendors must maintain commercial general liability coverage of $5,000,000 per occurrence, network security and privacy liability of $2,000,000, and professional liability of $2,000,000, and submit pricing in flat-price, net-price, or WAC-minus formats. The MMCAP cooperative extends procurement across Minnesota, Oregon, and other participating jurisdictions. Contract amendments for incumbent responders run through June 30, 2028, while new awards carry two-year terms with optional extensions at MMCAP's discretion.